Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strategies for neuroprotection.

C A Girkin1

  • 1Department of Ophthalmology, University of Alabama at Birmingham, The Eye Foundation Hospital, 35233, USA.

Journal of Glaucoma
|March 14, 2002
PubMed
Summary

Glaucoma research needs better animal models and clinical methods to test neuroprotective drugs. Improved quantification of glaucomatous damage is crucial for successful clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between thyroid problems and glaucoma.

The British journal of ophthalmology·2008
Same author

Axial length and optic disc size in normal eyes.

The British journal of ophthalmology·2006
Same author

Is there an association between pre-existing sleep apnoea and the development of glaucoma?

The British journal of ophthalmology·2006
Same author

Frequency doubling technology perimetry in non-arteritic ischaemic optic neuropathy with altitudinal defects.

The British journal of ophthalmology·2004
Same author

Central disorders of vision in humans.

Survey of ophthalmology·2001
Same author

Reproducibility of nerve fiber layer thickness measurements by use of optical coherence tomography.

Ophthalmology·2000

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma, a leading cause of irreversible blindness, involves progressive optic nerve damage.
  • Neuroprotective strategies offer potential for halting or slowing glaucoma progression.
  • Acute central nervous system (CNS) diseases have seen neuroprotective trial failures, offering lessons for glaucoma research.

Purpose of the Study:

  • To highlight the need for improved methodologies in preclinical and clinical glaucoma research.
  • To emphasize the importance of enhancing the assessment of neuroprotective agents for glaucoma.
  • To address the limitations of current methods in evaluating treatment efficacy for glaucoma.

Main Methods:

  • Review of challenges in translating neuroprotective strategies from animal models to clinical application in glaucoma.
  • Analysis of the inadequacy of current clinical outcome measures, such as visual fields, for quantifying glaucomatous progression.
  • Discussion of the necessity for developing superior animal models and refined clinical assessment tools.

Main Results:

  • Current methods for quantifying glaucomatous damage in clinical studies are insufficient to detect subtle progression.
  • The failure to adequately measure disease progression may lead to the misidentification of effective neuroprotective agents.
  • Existing clinical trial designs may not be sensitive enough to demonstrate the benefits of neuroprotective treatments.

Conclusions:

  • Enhanced animal models are essential for robust preclinical testing of glaucoma neuroprotective agents.
  • Improved clinical outcome measures are critical for the success of future glaucoma clinical trials.
  • Addressing methodological limitations is key to advancing neuroprotective therapies for glaucoma and preventing vision loss.

Related Experiment Videos